

Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region

Amman, 19 November 2025 – [Hikma Pharmaceuticals PLC](#) (Hikma), the multinational pharmaceutical company, has signed an exclusive licensing agreement with DGI Group LLC, a US-based company specialising in professional and commercial medical equipment and supplies. The agreement grants Hikma exclusive rights to commercialise Claritag®, an innovative, OTC skin tag removal device, across the MENA region.

Claritag® is a quick and effective skin tag removal device featuring patented Squeeze & Freeze® technology, offering safe and effective at home treatment for adults 21 years and older. It uses an innovative treatment technique causing skin tags to fall off naturally within seven to fourteen days. The device is a leading dermatologist-recommended brand for at home skin tag removal.

Requiring no assembly, Claritag® intuitively delivers an affordable and convenient medical-grade alternative to dermatologist visits. It is suitable for all skin types and tones, effectively treating skin tags avoiding freezing surrounding skin.

Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: "We are pleased to partner with DGI Group to bring Claritag® to the MENA region. This agreement significantly strengthens our growing Consumer Health portfolio by introducing an innovative and accessible solution to a common healthcare concern. Through its convenient and dermatologically tested design, Claritag® is in line with our efforts to provide safe and effective healthcare options that reach the everyday needs of our patients and communities."

This agreement underscores Hikma's ongoing commitment to diversify its consumer healthcare portfolio, enhancing access to high-quality, innovative healthcare solutions for patients across the region.

- ENDS -

For inquiries:

Mona Abdallah
Sr. Director, MENA Communications

MBAbdallah@Hikma.com / +962 6 5802900

Dana Alhusseini
Associate Director, MENA Communications

DAIhusseini@Hikma.com / +962 6 5802900

Zaina AlAtiyat
Manager, MENA Communications & Corporate Affairs

ZAIAtiyat@hikma.com / +962 6 5802900

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them.



Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com